Prakash Diwan, Chief Portfolio Strategist, Prakash Diwan's Wealth Circle, ECR told CNBC-TV18, "This is the beginning of a very strong momentum in Dr Reddys Laboratories. If one looks at the changes in the management which they have announced recently are people who actually hold a lot of promising potential in terms of taking the company forward. The company’s pipeline also is significantly stronger."
He further added, "The best point is the valuations, I don’t think valuations are stretched as compared to Sun Pharma or a Cipla or a Lupin relatively. I think the investor should hold on. Wait for another 20-25 percent of an upside in the next 9 to 12 months if the investor is patient enough."